MarginsXMarginsX
Home › Markets › Health Care › COCP

Cocrystal Pharma Inc. (COCP)

COCP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9777
-0.24% on the day
Market cap
$18.8M
Nano cap
Revenue · 2020
$2.0M
-69.3% on 2019
Net income · 2020
-$9.6M
-479.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/0001493152-22-007551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerCOCP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001412486
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2020

LineValue
Revenue$2.0M
Net income-$9.6M
Operating income-$9.6M
Net margin-479.0%
Operating margin-476.0%
Revenue growth-69.3%
Cash$33.0M
Total assets$54.2M
P/E (computed)Net income was not positive
P/S (computed)9.4×

Warning signs

Cash runway
3.3 months
$2.2M cash at June 30, 2026
Share count, 1 year
+87.8%
2025-08-12 to 2026-08-13 · +89.3% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$301K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$2.2M cash; operating cash flow -$2.0M a quarter.Report 2026-06-30
Shares outstanding19,263,200 (2026-08-13); 10,258,866 a year earlier; 10,173,790 three years earlier.Cover page 2026-08-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-23
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWeinberg & Company, P.A., Los Angeles, California, United StatesPCAOB Form AP 2026-04-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $301K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$105K-$3.2M-$2.5M$2.2MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
$225K-$2.3M-$2.3M$4.7MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
Not filed-$2.4M-$1.7M$7.0MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$2.0M-$1.4M$7.7MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.1M-$2.2M$4.8MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$2.3M-$2.9M$6.9MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
Not filed-$3.3M-$3.2M$9.9MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$4.9M-$5.1M$13.1MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-04-23
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-09-09
Latest proxyDEFA14A2026-05-27

Source: SEC EDGAR submissions feed, 674 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.8%
1 month-9.3%
3 months-10.9%
Year to date0.0%
1 year-4.9%
From 52-week high-37.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
LPCNLipocine Inc.$1.66-2.92%$18.4M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
CELUCelularity Inc.$0.6191-1.75%$20.1M
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
QNRXQuoin Pharmaceuticals Ltd.$3.56-3.78%$17.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier